<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Nimverta</title><link>https://www.nimverta.com/</link><description>Recent content on Nimverta</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Sun, 17 Aug 2025 12:00:00 +0200</lastBuildDate><atom:link href="https://www.nimverta.com/index.xml" rel="self" type="application/rss+xml"/><item><title>Dr. med. Stefan Zimmermann</title><link>https://www.nimverta.com/advisory/dr_med_stefan_zimmermann/</link><pubDate>Sun, 17 Aug 2025 12:00:00 +0200</pubDate><guid>https://www.nimverta.com/advisory/dr_med_stefan_zimmermann/</guid><description>Expert and specialist in Orthopaedic surgery and traumatology of the musculoskeletal system. Hirslanden, Zurich, Switzerland.</description></item><item><title>Dr. Sarika Singh</title><link>https://www.nimverta.com/advisory/dr_sarika_singh/</link><pubDate>Sun, 17 Aug 2025 12:00:00 +0200</pubDate><guid>https://www.nimverta.com/advisory/dr_sarika_singh/</guid><description>Senior Advisor at McNeely, Hare &amp;amp; War, LLP, New Jersey, USA. Expert in intellectual property and regulatory strategy, with extensive experience in patent prosecution, freedom-to-operate analysis, and regulatory pathways for biotech and pharmaceutical innovations in the US and global markets.</description></item><item><title>Dr. Tami Ehrmann Barr</title><link>https://www.nimverta.com/advisory/dr_tami_ehrmann_barr/</link><pubDate>Sun, 17 Aug 2025 12:00:00 +0200</pubDate><guid>https://www.nimverta.com/advisory/dr_tami_ehrmann_barr/</guid><description>Co-founder and former Chief Scientific Officer of Orthotreat, a bone biotech company based in Israel. Expert in regulatory affairs with deep experience in navigating clinical development and regulatory approval processes for bone and musculoskeletal therapies, including orphan drug designations and interactions with global health authorities.</description></item><item><title>Glenn Stanley</title><link>https://www.nimverta.com/advisory/glenn_stanley/</link><pubDate>Sun, 17 Aug 2025 12:00:00 +0200</pubDate><guid>https://www.nimverta.com/advisory/glenn_stanley/</guid><description>Key Opinion Leader (KOL) in osteoporosis and metabolic bone diseases, Prof. Serge Ferrari is a renowned clinical researcher at the University of Geneva, Switzerland.</description></item><item><title>Prof. Alessandro Angelini</title><link>https://www.nimverta.com/advisory/prof_alessandro_angelini/</link><pubDate>Sun, 17 Aug 2025 12:00:00 +0200</pubDate><guid>https://www.nimverta.com/advisory/prof_alessandro_angelini/</guid><description>Expert in peptide design and formulation, Co-Founder and CSO at Arzanya, and researcher at the European Center for Living Technology, Ca’ Foscari University of Venice, Italy.</description></item><item><title>Prof. Iván Durán</title><link>https://www.nimverta.com/advisory/prof_ivan_duran/</link><pubDate>Sun, 17 Aug 2025 12:00:00 +0200</pubDate><guid>https://www.nimverta.com/advisory/prof_ivan_duran/</guid><description>Expert on rare bone disease and creating research animal models for studying rare bone disease. University of Malaga, Spain.</description></item><item><title>Prof. Lothar Seefried</title><link>https://www.nimverta.com/advisory/prof_lothar_seefried/</link><pubDate>Sun, 17 Aug 2025 12:00:00 +0200</pubDate><guid>https://www.nimverta.com/advisory/prof_lothar_seefried/</guid><description>Leading clinician and researcher in the field of rare bone diseases, metabolic bone disorders, and orthopedic surgery and key opinion leader.</description></item><item><title>Prof. Serge Ferrari</title><link>https://www.nimverta.com/advisory/prof_serge_ferrari/</link><pubDate>Sun, 17 Aug 2025 12:00:00 +0200</pubDate><guid>https://www.nimverta.com/advisory/prof_serge_ferrari/</guid><description>Key Opinion Leader (KOL) in osteoporosis and metabolic bone diseases, Prof. Serge Ferrari is a renowned clinical researcher at the University of Geneva, Switzerland.</description></item><item><title>Prof. Shubhendu Palei</title><link>https://www.nimverta.com/advisory/prof_shubhendu_palei/</link><pubDate>Sun, 17 Aug 2025 12:00:00 +0200</pubDate><guid>https://www.nimverta.com/advisory/prof_shubhendu_palei/</guid><description>Expert in chemical biology and synthetic biology, with a focus on the design and development of bioactive molecules, peptide therapeutics, and chemical probes for biomedical applications.</description></item><item><title>Retard. Prof. Dr. med. Klaus Mohnike</title><link>https://www.nimverta.com/advisory/retard_prof_dr_med_klaus_mohnike/</link><pubDate>Sun, 17 Aug 2025 12:00:00 +0200</pubDate><guid>https://www.nimverta.com/advisory/retard_prof_dr_med_klaus_mohnike/</guid><description>Pediatric endocrinologist, Key Opinion Leader (KOL) in rare bone and metabolic disorders, and pioneer in the clinical development of enzyme replacement therapy for hypophosphatasia.</description></item><item><title>The Innovation Lab</title><link>https://www.nimverta.com/collaborators/john-doe/</link><pubDate>Fri, 01 Aug 2025 12:05:00 +0200</pubDate><guid>https://www.nimverta.com/collaborators/john-doe/</guid><description>The Innovation lab at the Univeristy of Science is akey collaborator &amp;hellip;</description></item><item><title>Dr. Gwang Jin Kim</title><link>https://www.nimverta.com/team/gwang-jin-kim/</link><pubDate>Fri, 01 Aug 2025 11:03:00 +0200</pubDate><guid>https://www.nimverta.com/team/gwang-jin-kim/</guid><description>Dr. Gwang Jin Kim is a specialist in search engine optimization and digital strategy, ensuring that Nimverta&amp;rsquo;s scientific mission and message reach a global audience.</description></item><item><title>Prof. Anjali Kusumbe</title><link>https://www.nimverta.com/team/anjali-kusumbe/</link><pubDate>Fri, 01 Aug 2025 11:02:00 +0200</pubDate><guid>https://www.nimverta.com/team/anjali-kusumbe/</guid><description>Prof. Anjali Kusumbe is a vascular biologist and expert in bone vasculature, ageing, and tissue regeneration.</description></item><item><title>Rob Chisholm</title><link>https://www.nimverta.com/team/rob-chisholm/</link><pubDate>Fri, 01 Aug 2025 11:01:00 +0200</pubDate><guid>https://www.nimverta.com/team/rob-chisholm/</guid><description>Rob Chisholm is an accomplished biopharmaceutical executive with over 25 years of global industry experience, specializing in bringing innovative therapies to market for patients with serious medical conditions.</description></item><item><title>Dr. Amit Singh</title><link>https://www.nimverta.com/team/amit-singh/</link><pubDate>Fri, 01 Aug 2025 11:00:00 +0200</pubDate><guid>https://www.nimverta.com/team/amit-singh/</guid><description>Dr. Amit Singh is a bioinformatic data scientist. He holds a bachelor&amp;rsquo;s degree in Physics and a master&amp;rsquo;s degree in Biochemistry.</description></item><item><title>Nimverta Secures Venture Kick Support to Advance Bone Regeneration Therapy</title><link>https://www.nimverta.com/blog/simple-blog-post-1/</link><pubDate>Tue, 24 Jun 2025 09:00:00 +0200</pubDate><guid>https://www.nimverta.com/blog/simple-blog-post-1/</guid><description>Nimverta, a Zurich-based biotech startup, has secured CHF 10,000 in funding from Venture Kick, entering a new phase in its journey to develop first-in-class peptide therapies for bone regeneration.</description></item><item><title>John Doe</title><link>https://www.nimverta.com/author/john-doe/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.nimverta.com/author/john-doe/</guid><description>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin sit amet vulputate augue. Duis auctor lacus id vehicula gravida.</description></item><item><title>Mark Dinn</title><link>https://www.nimverta.com/author/mark-dinn/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.nimverta.com/author/mark-dinn/</guid><description>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin sit amet vulputate augue. Duis auctor lacus id vehicula gravida.</description></item></channel></rss>